Progenics Pharmaceuticals, Inc. (PGNX) Reports In-Line Q1 Loss

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• SuperCom (SPCB) Tops Q3 EPS by 43c
• Ideal Power (IPWR) Tops Q2 EPS by 2c